| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Indiana University School of Medicine (S.E.F.), Indianapolis, Indiana 46202; and Pfizer Global Research and Development (T.K., D.F.-K., C.L., A.K.), Groton, Connecticut 06320
Address all correspondence and requests for reprints to: S. Edwin Fineberg, 3504 Mountain Lane, Mountain Brook, Alabama 35213. E-mail: efineber{at}iupui.edu.
Objective: To compare antibody responses to inhaled human insulin vs. sc human insulin and to determine whether insulin antibody binding is associated with adverse clinical consequences.
Research Design and Methods: Insulin antibody data from initial phase II/III trials were analyzed comparing the efficacy and safety of inhaled insulin with various agents, including sc insulin. Additionally, data from a 24-month extension of the phase III studies were examined. Data were pooled into the following three groups based on insulin treatment status at baseline: patients with type 1 diabetes, and patients with type 2 diabetes using insulin and not using insulin at baseline. Ig class analysis was also performed on randomly selected sera from type 1 patients at the end of the initial trials.
Results: In the initial trials, greater insulin antibody binding was observed in patients receiving inhaled insulin vs. sc insulin. The greatest antibody responses to inhaled insulin were observed in patients with type 1 diabetes [nonparametric comparison of medians at the end of the study, 22.0% binding (unadjusted 95% confidence interval: 19.5, 24.5)], and the lowest responses were observed in non-insulin-using patients with type 2 diabetes in which there was no difference in median values at the end of the study. There were no correlations between antibody binding and glycemic control (measured using glycosylated hemoglobin), insulin dose requirements, hypoglycemic events, or pulmonary function (measured by changes in forced expiratory volume in 1 sec and diffusion capacity of carbon monoxide). Antibody responses were IgG in type. Differences in antibody levels observed in patients with type 1 vs. type 2 diabetes were maintained over the 24-month extension trials. Peak antibody levels across all groups were generally observed after 6–12 months of insulin therapy. Inhaled insulin therapy was not associated with a greater incidence of allergy or other hypersensitivity reactions.
Conclusion: Inhaled insulin was observed to produce a larger antibody response than sc insulin. Insulin antibody binding has not been associated with adverse clinical consequences in trials to date.
This article has been cited by other articles:
 |
|
 |
|
  J. Rosenstock, W. T. Cefalu, P. A. Hollander, A. Belanger, F. G. Eliaschewitz, J. L. Gross, S. S. Klioze, L. B. St. Aubin, H. Foyt, M. Ogawa, et al. Two-Year Pulmonary Safety and Efficacy of Inhaled Human Insulin (Exubera) in Adult Patients With Type 2 Diabetes Diabetes Care, September 1, 2008; 31(9): 1723 - 1728. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. E. Fineberg, T. T. Kawabata, D. Finco-Kent, R. J. Fountaine, G. L. Finch, and A. S. Krasner Immunological Responses to Exogenous Insulin Endocr. Rev., October 1, 2007; 28(6): 625 - 652. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Q. Pham, H. Cohen, and V. Chu Inhaled Human [rDNA Origin] Insulin, a Novel Formulation for Diabetes Mellitus J. Clin. Pharmacol., July 1, 2007; 47(7): 890 - 903. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. S. Skyler, L. Jovanovic, S. Klioze, J. Reis, W. Duggan, and for the Inhaled Human Insulin Type 1 Diabetes Stud Two-Year Safety and Efficacy of Inhaled Human Insulin (Exubera) in Adult Patients With Type 1 Diabetes Diabetes Care, March 1, 2007; 30(3): 579 - 585. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Ghosh and A. Collier Inhaled insulins Postgrad. Med. J., March 1, 2007; 83(977): 178 - 181. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. T. McMahon and R. A. Arky Inhaled Insulin for Diabetes Mellitus N. Engl. J. Med., February 1, 2007; 356(5): 497 - 502. [Full Text] [PDF]
|
|
|
|
 |
|
 S. Bellary and A. H Barnett Inhaled insulin (Exubera(R)): combining efficacy and convenience Diabetes and Vascular Disease Research, December 1, 2006; 3(3): 179 - 185. [Abstract] [PDF]
|
|
|
|
 |
|
 Y. C Kudva and A. Basu Adjunctive inhaled insulin before meals improved glycaemic control more than adjunctive metformin in type 2 diabetes mellitus Evid. Based Med., December 1, 2006; 11(6): 176 - 176. [Full Text] [PDF]
|
|
|
|
|
|
A. H. Barnett, M. Dreyer, P. Lange, M. Serdarevic-Pehar, and on behalf of the Exubera Phase III Study Group An Open, Randomized, Parallel-Group Study to Compare the Efficacy and Safety Profile of Inhaled Human Insulin (Exubera) With Glibenclamide as Adjunctive Therapy in Patients With Type 2 Diabetes Poorly Controlled on Metformin Diabetes Care, August 1, 2006; 29(8): 1818 - 1825. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. H. Barnett, M. Dreyer, P. Lange, M. Serdarevic-Pehar, and on behalf of the Exubera Phase III Study Group An Open, Randomized, Parallel-Group Study to Compare the Efficacy and Safety Profile of Inhaled Human Insulin (Exubera) With Metformin as Adjunctive Therapy in Patients With Type 2 Diabetes Poorly Controlled on a Sulfonylurea. Diabetes Care, June 1, 2006; 29(6): 1282 - 1287. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. G. Teeter and R. J. Riese Dissociation of Lung Function Changes with Humoral Immunity during Inhaled Human Insulin Therapy Am. J. Respir. Crit. Care Med., June 1, 2006; 173(11): 1194 - 1200. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Morton-Eggleston and E. J Barrett Inhaled insulin. BMJ, May 6, 2006; 332(7549): 1043 - 1044. [Full Text] [PDF]
|
|
|
|
 |
|
 S. Bellary and A. H Barnett Review: Inhaled insulin: overcoming barriers to insulin therapy? The British Journal of Diabetes & Vascular Disease, May 1, 2006; 6(3): 103 - 108. [Abstract] [PDF]
|
|
|
|
 |
|
 J. Rosenstock, B. Zinman, L. J. Murphy, S. C. Clement, P. Moore, C. K. Bowering, R. Hendler, S.-P. Lan, and W. T. Cefalu Inhaled Insulin Improves Glycemic Control When Substituted for or Added to Oral Combination Therapy in Type 2 Diabetes: A Randomized, Controlled Trial Ann Intern Med, October 18, 2005; 143(8): 549 - 558. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |
